‘Corneal Endothelial Dystrophy (CED) – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the Corneal Endothelial Dystrophy, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Corneal Endothelial Dystrophy Disease Understanding Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of the eye. There are more than 20 types, each with different symptoms, all-cause a build-up of foreign material in one or more layers of the cornea. Corneal Endothelial Dystrophy or Fuchs’ endothelial dystrophy is a defect of the endothelial layer of the cornea. It can be either sporadic or inherited in an autosomal dominant manner. Fuchs’ endothelial dystrophy is characterized by the swelling of the cornea, which leads to glare, halo, and reduced visual acuity. In some cases, it can lead to corneal blindness.
Fuchs endothelial dystrophy (FED) or CED is characterized by an asymmetrical, bilateral, slowly progressive edema of the cornea in elderly patients and is found to be more prominent in females as compared to males. Deposits called guttae are generally detectable during an eye exam. They usually form in the middle of the cornea and eventually spread throughout the cornea. These guttae contribute to the ongoing cell death within the cornea, leading to worsening vision problems. Tiny blisters may develop on the cornea, which can burst and cause eye pain.
Corneal Endothelial Dystrophy Epidemiology The Corneal Endothelial Dystrophy epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the prevalent patient pool and their trends along with assumptions undertaken.
Key Findings The total prevalent cases of Corneal Endothelial Dystrophy patients are increasing in 7MM during the study period, i.e. 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted Corneal Endothelial Dystrophy symptoms epidemiology segmented as the Total Prevalent cases of Corneal Endothelial Dystrophy, Gender-specific cases of Corneal Endothelial Dystrophy, Age-specific cases of Corneal Endothelial Dystrophy, and Type-specific cases of Corneal Endothelial Dystrophy. The report includes the prevalent scenario of Corneal Endothelial Dystrophy symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Corneal Endothelial Dystrophy Epidemiology The epidemiology segment also provides the Corneal Endothelial Dystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total prevalent cases of Corneal Endothelial Dystrophy associated in 7MM countries were 6,194,906 in 2017.
• As per the estimates, the United States has the largest prevalent population of Corneal Endothelial Dystrophy.
• Among the EU5 countries, Germany had the highest prevalent cases of Corneal Endothelial Dystrophy, followed by Italy. On the other hand, the UK had the lowest prevalent cases with 1,472,742 cases in 2017.
Scope of the Report • The Corneal Endothelial Dystrophy report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis, and treatment patterns.
• The Corneal Endothelial Dystrophy Epidemiology Report and Model provide an overview of the risk factors and global trends of Corneal Endothelial Dystrophy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Corneal Endothelial Dystrophy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Corneal Endothelial Dystrophy.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Gender-specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Age-Specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• The report provides the segmentation of the Corneal Endothelial Dystrophy epidemiology by Severity-Specific Prevalent Cases of Corneal Endothelial Dystrophy in 7MM.
• 11-Year Forecast of Corneal Endothelial Dystrophy epidemiology • 7MM Coverage
• Total Prevalent Cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Gender-specific cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Age-specific cases of Corneal Endothelial Dystrophy
• Prevalent Cases according to segmentation: Type-specific cases of Corneal Endothelial Dystrophy
We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered • What will be the growth opportunities in the 7MM for the patient population of Corneal Endothelial Dystrophy?
• What are the key findings of the Corneal Endothelial Dystrophy epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017–2030)?
• What would be the total number of patients of Corneal Endothelial Dystrophy across the 7MM during the forecast period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017–2030)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017–2030)?
• What are the disease risk, burden, and unmet needs of the Corneal Endothelial Dystrophy?
• What are the currently available treatments of Corneal Endothelial Dystrophy?
Reasons to buy The Corneal Endothelial Dystrophy epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global Corneal Endothelial Dystrophy market
• Quantify patient populations in the global Corneal Endothelial Dystrophy market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Corneal Endothelial Dystrophy therapeutics in each of the markets covered
• Understand the magnitude of Corneal Endothelial Dystrophy population by its prevalent cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Gender-specific cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Age-specific cases
• Understand the magnitude of Corneal Endothelial Dystrophy population by its Severity-specific cases
• The Corneal Endothelial Dystrophy epidemiology report and model were written and developed by Masters and PhD level epidemiologists
• The Corneal Endothelial Dystrophy Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources
Key Assessments • Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered • The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017–2030
The late-onset form of Fuchs endothelial dystrophy is a common condition, affecting people over the age of 40 in the United States. This disease typically starts in the 30s and 40s, but many people with Fuchs’ dystrophy do not develop symptoms until they reach their 50s or 60s. The early-onset variant of Fuchs endothelial dystrophy is comparatively rare, although the exact prevalence is unknown.
Several prevalence studies have placed the prevalence in the United States between 4% and 7% of people aged 40 and above, the prevalence being higher in the Caucasian population. In Europe, 4.5–9% of people aged 40 and above are expected to suffer from Fuchs’ dystrophy. However, the Japanese prevalence estimates are lower. Kitagawa et al. (2002) conducted a Japanese study with 299 subjects and found the prevalence to be 3.7%.
Moreover, it must be noted that all these studies use corneal guttata as a surrogate for early-stage Fuchs’ disease. According to our primary market research, most of these patients would have very mild or no symptoms, which might not need intervention; approximately 5% of patients with corneal guttata become symptomatic and have disease progression that warrants surgical intervention.
Our reports have been used by over 10K customers, including:
The Europe Surgical Robotic Systems Market would witness market growth of 20.5% CAGR during the forecast period (2020-2026). In recent years, developed robots permits doctors and surgeons to perform complicated surgeries and procedures with high adaptability and accuracy. Surgical robotic arms provide excellent control over tasks that...
A critical aspect of efficiency in healthcare organizations is asset management. Hospitals have thousands of assets to track and maintain, and failure of which results in increased waste and downtime, restricted patient flow, decreased quality of care, poor employee productivity, and financial losses.Hospitals are demanding more holistic solutions...
Executive summary mHealth refers to the application of telecommunications in medicine and includes everything from connected medical devices to digital care programs. The adoption of mHealth solutions in healthcare is driven by a wide range of incentives, related to everything from demographics and technology development...
Osseointegration Implants Market Size, Share & Trends Analysis Report By End Use (ASCs, Hospitals, Dental Clinics), By Product (Dental, Knee, Hip, Spinal Implants), By Region, And Segment Forecasts, 2018 - 2026 The global osseointegration implants market size is expected to reach USD 9.3 billion by 2026, according to a new report by...
Global Proton Therapy Market & Forecast (12 Countries Market Data), Patients Treated at Proton Therapy Centers, Reimbursement Policies Global Proton Therapy market will surpass US$ 18 Billion by 2018. According to Renub research analysis, the global proton therapy market will be growing at a rapid...
Summary BioTelemetry Research (BioTelemetry), formerly Cardiocore, is a subsidiary of BioTelemetry, Inc., healthcare service provider that offers imaging services. The center offers cardiac testing services such as imaging and respiratory testing services. Its services comprise electrocardiography, holter monitoring, ambulatory...
Summary Shin Nippon Biomedical Laboratories Ltd (SNBL) is a healthcare service provider that provides drug and clinical development service to biopharmaceutical companies. Its preclinical services include SNBL USA preclinical expertise, SNBL preclinical drug safety research (DSR) expertise, general toxicology, immunotoxicology...
Global RFID Kanban systems market is expected to reach USD 1.1 Billion by 2020. Increasing cases of stock outs, over inventory, clerical errors and growing demand for real time asset and inventory tracking are some factors expected to drive market growth over the next six years. Furthermore, high cost incurred due to medication expiration,...
83 pages •
By Transparency Market Research
• Sep 2015
Medical cameras and microscopes are widely used in surgical and pathological applications. Increase in the geriatric population across the globe and prevalence of diseases among them have led to a rise in the medical procedures performed. The pathological microscopes segment is driven by increase in demand in diagnostic labs and physician...
Summary AioCare (AioCare), formerly known as Biosign Technologies Inc. is a medical device company that manufactures, distributes and exports health information technology products. The company offers products, which include pulsewave, pulsewave MAX and healthanywhere. Its healthanywhere is a software application that helps clinics,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.